However, the anti-tumor effects of anti-CTLA4 treatment largely rely on the antibody-dependent cellular cytotoxicity (ADCC) mediated depletion of tumor-infiltrating Tregs (56, 57). This evidence concerns the gene CTLA4 and neoplasm.